SI0801564T1 - Use of nebivolol as an anti-atherogenic - Google Patents

Use of nebivolol as an anti-atherogenic

Info

Publication number
SI0801564T1
SI0801564T1 SI9530591T SI9530591T SI0801564T1 SI 0801564 T1 SI0801564 T1 SI 0801564T1 SI 9530591 T SI9530591 T SI 9530591T SI 9530591 T SI9530591 T SI 9530591T SI 0801564 T1 SI0801564 T1 SI 0801564T1
Authority
SI
Slovenia
Prior art keywords
alpha
nebivolol
atherogenic
chromanmethanol
iminobis
Prior art date
Application number
SI9530591T
Other languages
English (en)
Slovenian (sl)
Inventor
Chaffoy De Courcelles Didier R.G.G. De
Anne Simone Josephine Lesage
Josepha Eduarda Maria Francisca Leysen
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of SI0801564T1 publication Critical patent/SI0801564T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
SI9530591T 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic SI0801564T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28
PCT/EP1995/005174 WO1996019987A1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic
EP95942209A EP0801564B1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic

Publications (1)

Publication Number Publication Date
SI0801564T1 true SI0801564T1 (en) 2002-08-31

Family

ID=8217503

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9530591T SI0801564T1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic

Country Status (20)

Country Link
US (2) US5874461A (hu)
EP (1) EP0801564B1 (hu)
JP (1) JPH10511655A (hu)
KR (1) KR100264348B1 (hu)
CN (1) CN1167418C (hu)
AT (1) ATE214924T1 (hu)
AU (1) AU700364B2 (hu)
CA (1) CA2207333C (hu)
CZ (1) CZ287513B6 (hu)
DE (1) DE69526120T2 (hu)
DK (1) DK0801564T3 (hu)
ES (1) ES2176354T3 (hu)
FI (1) FI118884B (hu)
HU (1) HU226208B1 (hu)
NO (1) NO315687B1 (hu)
NZ (1) NZ298074A (hu)
PT (1) PT801564E (hu)
SI (1) SI0801564T1 (hu)
SK (1) SK282144B6 (hu)
WO (1) WO1996019987A1 (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100264348B1 (ko) * 1994-12-28 2000-08-16 디르크 반테 항-죽종형성제로서 네비볼롤을 함유하는 조성물
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
JP2000207219A (ja) * 1999-01-18 2000-07-28 Fujitsu Ten Ltd 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
DE60233140D1 (de) 2001-05-02 2009-09-10 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
AU2003287250B9 (en) * 2002-10-30 2010-01-28 Ptc Therapeutics, Inc. Identifying therapeutic compounds based on their physical-chemical properties
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
CA2583087C (en) * 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Chroman derivatives
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
MX2007000911A (es) 2004-07-30 2007-04-12 Torrent Pharmaceuticals Ltd Nevibolol y sus sales farmaceuticamente aceptables, proceso para su preparacion y composiciones farmaceuticas de nevibolol.
AP2764A (en) * 2005-01-31 2013-09-30 Mylan Lab Inc Hydroxylated nebivolol metabolites
PL1888059T3 (pl) 2005-06-01 2015-06-30 Bioelectron Tech Corp Środki terapeutyczne aktywne wobec układów redoks do leczenia chorób mitochondrialnych i innych zaburzeń oraz modulacja biomarkerów energetycznych
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ, インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
EP2220030B1 (en) 2007-11-06 2016-01-13 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
JP5710277B2 (ja) 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ, インコーポレイテッド 酸化ストレス疾患の処置のための2−置換−p−キノン誘導体
MX2011002318A (es) 2008-09-10 2011-05-10 Edison Pharmaceuticals Inc Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
WO2010045220A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
MX2011006549A (es) * 2008-12-19 2011-07-20 Schering Corp Suplemento alimenticio para el cultivo de celula de mamifero y metodos de uso.
EP2424495B1 (en) 2009-04-28 2018-01-17 Bioelectron Technology Corporation Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
US20130065910A1 (en) * 2010-06-04 2013-03-14 Comprehensive Drug Enterprises Ltd. Oral meclizine aqueous formulations with taste flavoring agent
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
WO2016062272A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 免疫疾病用药物在制备抑制癌症的医药组合物中的应用
PT3233786T (pt) 2014-12-16 2022-05-06 Ptc Therapeutics Inc Formas polimórficas e amorfas de (r)-2-hidroxi-2-metil-4- (2,4,5-trimetil-3,6-dioxociclohexa-1,4-dienil)butanamida
CA3008849A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
KR100264348B1 (ko) * 1994-12-28 2000-08-16 디르크 반테 항-죽종형성제로서 네비볼롤을 함유하는 조성물

Also Published As

Publication number Publication date
CA2207333C (en) 2006-10-17
JPH10511655A (ja) 1998-11-10
SK85697A3 (en) 2000-04-10
US5874461A (en) 1999-02-23
KR100264348B1 (ko) 2000-08-16
CZ287513B6 (en) 2000-12-13
ES2176354T3 (es) 2002-12-01
AU700364B2 (en) 1999-01-07
NO972980D0 (no) 1997-06-26
HUT77927A (hu) 1998-11-30
EP0801564B1 (en) 2002-03-27
AU4347796A (en) 1996-07-19
CZ191997A3 (cs) 1999-01-13
DE69526120T2 (de) 2002-11-28
CN1171739A (zh) 1998-01-28
NZ298074A (en) 2001-01-26
NO315687B1 (no) 2003-10-13
DE69526120D1 (de) 2002-05-02
EP0801564A1 (en) 1997-10-22
DK0801564T3 (da) 2002-07-15
FI972793A (fi) 1997-06-27
FI118884B (fi) 2008-04-30
CA2207333A1 (en) 1996-07-04
US6075046A (en) 2000-06-13
NO972980L (no) 1997-06-26
HU226208B1 (en) 2008-06-30
PT801564E (pt) 2002-09-30
SK282144B6 (sk) 2001-11-06
CN1167418C (zh) 2004-09-22
ATE214924T1 (de) 2002-04-15
MX9704669A (es) 1997-09-30
WO1996019987A1 (en) 1996-07-04
FI972793A0 (fi) 1997-06-27

Similar Documents

Publication Publication Date Title
SI0801564T1 (en) Use of nebivolol as an anti-atherogenic
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
BG107537A (en) Method for the inhibition of human tnf alpha activity and its application
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
EP0923376A4 (en) TREATMENT OF ASTHMA AND RESPIRATORY DISEASES
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
DE59904180D1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG105275A (en) Tan-1057 derivatives
BG102667A (en) Diosgenine-containing composition
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
BG102707A (en) New triazolopurinpurines, method for their preparation and appplication as medicamentous forms
IL143382A0 (en) Human adult astrocytes, their preparation and uses thereof
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
AU1278600A (en) Novel therapeutic application of nicergoline
AU2392797A (en) Use of benzonaphthalene derivatives for the manufacture of medicaments for the treatment of diseases of the nervous system
WO1996025931A3 (en) Use of fused benzothiazoles as neuroprotectants
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
MX9706931A (es) Derivados de amida de acido-2-ciano-3,5-dihidroxi-hex-2-eno-carboxilico.
BG102864A (en) Application of phosphonic acid esters for the treatment of functional disorders of the brain and depressions
UA32580C2 (uk) Засіб для лікування паралітичної непрохідності кишечнику
UA10259A (uk) Протинабряковий лікарський препарат "нейрополіосм"